Neuronetics, Inc.

STIM

US64131A1051

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 09:53:16 2024-04-24 am EDT			5-day change	1st Jan Change
3.895 ^USD	+0.91%		-5.05%	+29.66%

Apr. 10	Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	CI
Mar. 28	Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	CI

NEURONETICS, INC. : Regulation FD Disclosure (form 8-K)

August 02, 2022 at 07:35 am EDT

Item 7.01 Regulation FD Disclosure.

On August 2, 2022, Neuronetics, Inc. posted its August 2022 investor presentation and supplemental financial and operating information to its website at http://ir.neuronetics.com.

Latest news about Neuronetics, Inc.

Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation	Apr. 10	CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board	Mar. 28	CI
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21	Mar. 25	DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise	Mar. 25	MT
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy	Mar. 25	CI
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network	Mar. 07	CI
Transcript : Neuronetics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M	Mar. 05	MT
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 05	CI
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 05	CI
North American Morning Briefing : S&P 500 Futures -2-	Mar. 05	DJ
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System	Feb. 12	CI
Top Premarket Gainers	Jan. 25	MT
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023	Jan. 08	CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory	Dec. 18	CI
Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan	Dec. 04	CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements	Nov. 13	CI
Transcript : Neuronetics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M	Nov. 07	MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Nov. 07	CI
Neuronetics, Inc. Enters into Fifth Amendment to Loan and Security Agreement with SLR Investment Corp	23-10-03	CI
Neuronetics Draws Down Remaining $22.5 Million From SLR Capital Credit Facility	23-10-03	MT
Neuronetics, Inc. Draws Down Remaining $22.5 Million Available Under Credit Facility	23-10-03	CI
Neuronetics, Inc.(NasdaqGM:STIM) dropped from S&P Global BMI Index	23-09-18	CI

Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Neuronetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.86 USD

Average target price

7 USD

Spread / Average Target

+81.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
NEURONETICS, INC.	+29.66%	116M
THERMO FISHER SCIENTIFIC	+10.00%	219B
DANAHER CORPORATION	+9.70%	187B
INTUITIVE SURGICAL, INC.	+13.29%	134B
BOSTON SCIENTIFIC CORPORATION	+27.36%	101B
SIEMENS HEALTHINEERS AG	+0.87%	62.27B
EDWARDS LIFESCIENCES CORPORATION	+16.65%	52.82B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-2.10%	47.49B
AGILENT TECHNOLOGIES, INC.	-0.24%	40.79B
GE HEALTHCARE TECHNOLOGIES INC.	+11.73%	39.35B

Other Advanced Medical Equipment & Technology

Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

NEURONETICS, INC. : Regulation FD Disclosure (form 8-K)

Latest news about Neuronetics, Inc.

Chart Neuronetics, Inc.

Company Profile

Income Statement Evolution

Ratings for Neuronetics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Advanced Medical Equipment & Technology